FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed reforms to the Orange Book patent listing procedures would allow companies to list patents covering polymorphs and some types of manufacturing processes